Factors Informing First-Line Treatment Selection in EGFR-Mutated NSCLC

Narjust Florez, MD, reviews key clinical and molecular variables that guide first-line therapy selection in EGFR-mutated advanced non–small cell lung cancer (NSCLC). Florez emphasizes the importance of identifying EGFR mutation subtypes and co-mutations, central nervous system involvement, and patient performance status when choosing among targeted options. She also discusses how toxicity profiles, comorbidities, and patient preferences intersect with efficacy data to individualize frontline treatment strategies.